Herbert Irving Comprehensive Cancer Center (HICCC) is a National Cancer Institute NCI-designated Cancer Center, founded in 1911 and located at NewYork-Presbyterian / Columbia University Irving Medical Center (NYP/CUIMC).
The HICCC has more than 250 faculty members, 12 core facilities, and eight research programs within three divisions.[1]
There are eight research programs at HICCC divided into three divisions. The basic research division includes programs in cancer regulatory networks and cancer genetics and epigenetics. Programs in the disease-specific division focus on breast cancer, hematological cancer, prostate cancer, and neuro-oncology. The population science division includes cancer epidemiology and prevention, control, and disparities.
The center is currently receiving over $33 million in funding from the National Institutes of Health.[2]
Patients are treated at NewYork-Presbyterian Hospital/Columbia. HICCC physicians treat more than 3,500 patients annually. There are over 200 clinical trials available to patients.[3]
First opened in 1911 as the Institute for Cancer Research, it soon moved to its current location at Columbia-Presbyterian Medical Center. HICC received its NCI designation in 1972, being promoted to comprehensive status in 1979.
After a 1998 merger, the campus name was changed to Columbia University Medical Center, remaining an academic medical center and becoming the largest campus of NewYork-Presbyterian Hospital.
In 2017, Herbert and Florence Irving gave a transformative $700 million gift to Columbia University and NewYork-Presbyterian to dramatically advance research and clinical programs for the treatment of cancer. In recognition of a lifetime of philanthropy, the Hospital and the University jointly renamed the campus to its current name, Columbia University Irving Medical Center.[4]
HICCC was previously led by Stephen G. Emerson, and the current director is Anil K Rustgi, MD, with Gary Schwartz as the deputy director.[5]